throbber
Case 2:13-cv-00391-ES-JAD Document 313 Filed 08/15/16 Page 1 of 5 PageID: 6096
`
`Charles M. Lizza
`William C. Baton
`SAUL EWING LLP
`One Riverfront Plaza, Suite 1520
`Newark, NJ 07 102-5426
`(973) 286-6700
`clizza@saul.com
`
`Sean R. Kelly (srk@saiber.com)
`Katherine A. Escanlar (kescanlar@saiber.com)
`SAIBER LLC
`18 Columbia Turnpike
`Suite 200
`Florham Park, NJ 07932
`(973) 645-4801
`
`Attorneysfor Plainqffs
`Jazz Pharmaceuticals, Inc. and
`Jazz Pharmaceuticals Ireland Limited
`
`Attorneysfor Defendant
`Par Pharmaceutical, Inc.
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`Civil Action No. 13-391 (ES)(JAD)
`(consolidated)
`
`(Filed Electronically)
`
`JAZZ PHARMACEUTICALS, INC. and
`JAZZ PHARMACEUTICALS IRELAND
`LIMITED,
`
`Plaintiffs,
`
`V.
`
`ANNEAL PHARMACEUTICALS LLC, et
`aL
`
`Defendants.
`
`STIPULATION AN]) ORDER OF DISMISSAL
`
`Plaintiffs Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited (collectively,
`
`“Jazz”) and Defendant Par Pharmaceutical Inc. (“Par”), by their undersigned counsel, hereby
`
`stipulate and agree, subject to the approval of the Court, that:
`
`WHEREAS, in this action, Jazz has brought claims against Par for infringement of certain
`
`patents, including, inter alia, U.S. Patent Nos. 6,472,431 (“the ‘431 patent”), 6,780,889 (“the ‘889
`
`patent”), 7,262,219 (“the ‘219 patent”), 7,851,506 (“the ‘506 patent”), 8,263,650 (“the ‘650
`
`patent”), 8,324,275 (“the ‘275 patent”), 8,461,203 (“the ‘203 patent”), 8,859,619 (“the ‘619
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 313 Filed 08/15/16 Page 2 of 5 PageID: 6097
`
`patent”), and 8,952,062 (“the ‘062 patent”) (collectively, the “Formulation Patents”) in connection
`
`with Par’s submission of Abbreviated New Drug Application (“ANDA”) No. 205403;
`
`WHEREAS, pursuant to Section 505 ofthe Federal Food Drug and Cosmetic Act
`
`(“FFDCA”), Par filed ANDA No. 205403 (“Par’s ANDA”) seeking approval to engage in the
`
`commercial use, manufacture, sale, offer for sale, or importation of 500 mg/mi sodium oxybate oral
`
`solution (“Par’s Proposed Product”), before the Formulation Patents expire;
`
`WHEREAS, Par has amended its ANDA No. 205403 to remove the certification under
`
`21 U.S.C. § 355(j)(2)(A)(vii)(IV) with respect to the ‘889, ‘219, ‘506, ‘650, ‘275, ‘619, and ‘062
`
`patents, submitted certifications for those patents under Section 505 ofthe FFDCA, 21 U.S.C. §
`
`355(j)(2)(A)(vii)(III) (“Par’s Paragraph III Certifications”), and is no longer seeking FDA approval
`
`of ANDA No. 205403 prior to the expiration of the Formulation Patents;
`
`WHEREAS, Jazz has agreed to dismiss the Formulation Patents from this action against Par
`
`without prejudice based on Par’s agreement to the injunction described below if Par changes its
`
`Paragraph ifi Certifications for any ofthe Formulation Patents back to certifications under 21
`
`U.S.C. § 355(j)(2)(A)(vii)(IV);
`
`WHEREAS, the parties agree that, if (i) Par amends ANDA No. 205403 to contain a
`
`certification under 21 U.S.C.(j)(2)(A)(vii)(IV) for any of the foregoing patents and (ii) Jazz
`
`brings an action for infringement of at least one patent that is the subject of the first such
`
`amendment of the certification (“Jazz’s First New Formulation Patent Action”) within 45 days of
`
`receiving a complete notice from Par under 21 U.S.C. § 355(b)(3) regarding each such patent
`
`identified in the first amended certification (“Par’s First New Paragraph IV Notice”), then Par
`
`agrees to be enjoined from launching its Proposed Product for the shorter of 30 months from Jazz’s
`
`1
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 313 Filed 08/15/16 Page 3 of 5 PageID: 6098
`
`receipt of Par’s First New Paragraph 1V Notice or the duration of Jazz’s First New Formulation
`
`Patent Action;
`
`NOW, THEREFORE, it is hereby stipulated and agreed by and between the parties that:
`
`1.
`
`Pursuant to Federal Rules of Civil Procedure 41 (a)( 1 )(A)(ii) and 41(c) that the
`
`following counts, affirmative defenses, and counterclaims are dismissed without prejudice, each
`
`party to bear its own costs, disbursements, and attorney fees:
`
`• Counts I-Vu of the Complaint in C.A. No. 13-7884-ES-JAD (D.I. 1), Par’s first
`
`through fourteenth Affirmative Defenses in C.A. No. 13-7884-ES-JAD (D.I. 7), and
`
`Par’s Counterclaim Counts I-X1V (id.);
`
`• Count I of the Complaint in C.A. No. 15-00173-ES-JAD (D.I. 1), Par’s first, second,
`
`and thirdAffirmative Defenses in C.A. No. 15-00173-ES-JAD (D.I. 9), and Par’s
`
`Counterclaim Counts I-TI (id.); and
`
`• Count II of the Complaint in C.A. No. 15-03217-ES-JAD (D.I. 1), as well as Par’s
`
`first, second, third,, and fourth Affirmative Defenses in 15-03217-ES-lAD (D.I. 12),
`
`and Par’s Counterclaim Counts I-HI (id.).’
`
`2.
`
`If Par changes its Paragraph III Certifications for any ofthe Formulation Patents
`
`back to certifications under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), and Jazz brings a First New
`
`Formulation Patent Action within 45 days of receiving Par’s First New Paragraph IV Notice, Par
`
`will request that the FDA institute a new 30-month stay of approval with regard to Par’s ANDA.
`
`If the FDA does not enter a new 30-month stay of approval pursuant to Par’s Request, then Par shall
`
`The dismissal of the parties’ claims, defenses, and counterclaims with respect to the
`Formulation Patents asserted against Par in this Action shall not result in the dismissal of claims,
`defenses, and counterclaims with respect to the other patents Jazz has asserted against Par in this
`Action. Nor shall it result in the dismissal of claims, defenses, and counterclaims in this Action
`with respect to Amneal Pharmaceuticals LLC, Watson Laboratories, Inc., Lupin Ltd., Lupin
`Pharmaceuticals, Inc., and Lupin Inc.
`
`2
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 313 Filed 08/15/16 Page 4 of 5 PageID: 6099
`
`be enjoined from launching its Proposed Product for the shorter of 30 months from Jazz’s receipt of
`
`Par’s First New Paragraph 1V Notice, the duration of Jazz’s First New Formulation Patent Action,
`
`or the expiration of all of the Formulation Patents. The duration of any stay or injunction relating to
`
`the Formulation Patents shall not affect the duration of any other applicable stay relating to Par’s
`
`ANDA No. 205403.
`
`3.
`
`This Court retains jurisdiction over Jazz and Par for purposes of enforcing this
`
`Stipulation and Order of Dismissal.
`
`4.
`
`The Clerk ofthe Court is directed to enter this judgment forthwith.
`
`3
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 313 Filed 08/15/16 Page 5 of 5 PageID: 6100
`
`Dated: August 12, 2016
`
`By:
`
`5/ Charles M. Lizza
`Charles M. Lizza
`William C. Baton
`SAUL EWING LLP
`One Riverfront Plaza, Suite 1520
`Newark, NJ 07 102-5426
`(973) 286-6700
`clizza@saul.com
`
`Attorneysfor Plaintiffs
`Jazz Pharmaceuticals, Inc. and
`Jazz Pharmaceuticals Ireland
`Limited
`
`By:
`
`s/ Sean R. Kelly
`Sean R. Kelly (srk@saiber.com)
`Katherine A. Escanlar
`(kescanlar@saiber.com)
`SAIBER LLC
`18 Columbia Turnpike
`Suite 200
`Florham Park, NJ 07932
`(973) 645-4801
`
`Attorneysfor Defendant
`Par Pharmaceutical Inc.
`
`OfCounsel:
`
`OfCounsel:
`
`Richard J. Berman
`Janine A. Carlan
`Bradford C. Frese
`Ahmed Abdel-Rahman
`ARENT Fox LLP
`1717 K Street NW
`Washington, D.C. 20006-5344
`(202) 857-6000
`richard.berman@arentfox.com
`janine.carlan@arentfox.com
`bradford.frese@arentfox.com
`ahmed.abdel-rahman@arentfox.com
`
`F. Dominic Cerrito
`Eric C. Stops
`Evangeline Shih
`Gabriel P. Brier
`QuINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22’ Floor
`New York, New York 10010
`(212) 849-7000
`
`Richard G. Greco
`RICHARD G. GRECO PC
`90 State Street, Suite 700
`Albany, New York 12207
`(212) 203-7625
`
`IT IS on this/
`
`TI-V1 HO’TO,RABLE\ESTHER SALAS
`7JITED S
`)STRICT JUDGE
`
`4
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket